Get to know our clinical trials
Clinical trial of the Bcl-2 inhibitor BGB-11417 in patients with mature B-lymphocyte malignancies.
THE OBJECTIVE OF THIS TRIAL IS TO DETERMINE SAFETY AND TOLERABILITY; TO DEFINE THE MAXIMUM TOLERATED DOSE (MTD) AND RECOMMENDED DOSE FOR PHASE II (DRF2); AND TO EVALUATE THE SAFETY AND TOLERABILITY OF THE STEP-UP DOSING SCHEDULE AND DRF2 OF BGB-11417, IN MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB.
- PHASE I/IB OPEN-LABEL DOSE ESCALATION AND DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR BGB-11417 IN PATIENTS WITH MATURE B-LYMPHOCYTE MALIGNANCIES
- Code EudraCT: 2020-004641-37
- Protocol number: BGB-11417-101
- Promoter: BeiGene, Ltd.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.